Salarius Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Decoy Therapeutics Inc., signaling a notable investment in the company's common stock.
CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 9.9% beneficial ownership stake in Decoy Therapeutics Inc., primarily through warrants.
CVI Investments, managed by Heights Capital Management, disclosed a 9.9% beneficial ownership stake in Salarius Pharmaceuticals, Inc., totaling 362,499 shares.
Intracoastal Capital LLC and its managers, Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Salarius Pharmaceuticals, Inc. common stock.
C/M Capital Master Fund and related entities filed a Schedule 13G, reporting zero beneficial ownership in Salarius Pharmaceuticals, Inc. as of October 7, 2025.